Literature DB >> 33910872

Acute Toxicity in Hypofractionated/Stereotactic Prostate Radiotherapy of Elderly Patients: Use of the Image-guided Radio Therapy (IGRT) Clarity System.

Rossella DI Franco1, Valentina Borzillo2, Domingo Alberti2, Gianluca Ametrano2, Angela Petito2, Andrea Coppolaro2, Ilaria Tarantino2, Sabrina Rossetti3, Sandro Pignata3, Gelsomina Iovane3, Sisto Perdonà4, Giuseppe Quarto4, Giovanni Grimaldi4, Alessandro Izzo4, Luigi Castaldo4, Raffaele Muscariello4, Marcello Serra2, Gaetano Facchini5, Paolo Muto2.   

Abstract

BACKGROUND: The use of intra-fractional monitoring and correction of prostate position with the Image Guided Radio Therapy (IGRT) system can increase the spatial accuracy of dose delivery. Clarity is a system used for intrafraction prostate-motion management, it provides a real-time visualization of prostate with a transperineal ultrasound. The aim of this study was to evaluate the use of Clarity-IGRT on proper intrafraction alignment and monitoring, its impact on Planning Tumor Volume margin and on urinary and rectal toxicity in elderly patients not eligible for surgery. PATIENTS AND METHODS: Twenty-five elderly prostate cancer patients, median age=75 years (range=75-90 years) were treated with Volumetric Radiotherapy and Clarity-IGRT using 3 different schemes: A) 64.5/72 Gray (Gy) in 30 fractions on prostate and seminal vesicles (6 patients); B) 35 Gy in 5 fractions on prostate and seminal vesicles (12 patients); C): 35 Gy in 5 fractions on prostate (7 patients). Ultrasound identification of the overlapped structures to the detected ones during simulation has been used in each session. A specific software calculates direction and entity of necessary shift to obtain the perfect match. The average misalignment in the three-dimensional space has been determined and shown in a box-plot.
RESULTS: All patients completed treatment with mild-moderate toxicity. During treatment, genitourinary toxicity was 32% Grade 1; 4% Grade 2, rectal was 4% Grade 1. At follow-up of 3 months, genitourinary toxicity was 20% Grade 1; 4% Grade 2, rectal toxicity was 4% Grade 2. At follow-up of 6 months, genitourinary toxicity was 4% Grade 1; 4% Grade 2. Rectal toxicity was 4% Grade 2.
CONCLUSION: Radiotherapy with the Clarity System allows a reduction of PTV margins, the amount of fractions can be reduced increasing the total dose, not exacerbating urinary and rectal toxicity with greater patient's compliance. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Prostate cancer; hypofractionated radiotherapy; radiotherapy; tracking; ultrasound

Mesh:

Year:  2021        PMID: 33910872      PMCID: PMC8193305          DOI: 10.21873/invivo.12447

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  46 in total

Review 1.  From radiobiology to technology: what is changing in radiotherapy for prostate cancer.

Authors:  Berardino De Bari; Alba Fiorentino; Stefano Arcangeli; Pierfrancesco Franco; Rolando Maria D'Angelillo; Filippo Alongi
Journal:  Expert Rev Anticancer Ther       Date:  2014-03-03       Impact factor: 4.512

2.  The ViewRay system: magnetic resonance-guided and controlled radiotherapy.

Authors:  Sasa Mutic; James F Dempsey
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

3.  First evaluation of the feasibility of MLC tracking using ultrasound motion estimation.

Authors:  Martin F Fast; Tuathan P O'Shea; Simeon Nill; Uwe Oelfke; Emma J Harris
Journal:  Med Phys       Date:  2016-08       Impact factor: 4.071

Review 4.  Stereotactic body radiotherapy for prostate cancer.

Authors:  D R Henderson; A C Tree; N J van As
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-02-21       Impact factor: 4.126

5.  Intra-fraction motion of the prostate is a random walk.

Authors:  H Ballhausen; M Li; N-S Hegemann; U Ganswindt; C Belka
Journal:  Phys Med Biol       Date:  2014-12-30       Impact factor: 3.609

6.  Prostate alpha/beta revisited -- an analysis of clinical results from 14 168 patients.

Authors:  Alexandru Dasu; Iuliana Toma-Dasu
Journal:  Acta Oncol       Date:  2012-09-12       Impact factor: 4.089

7.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.

Authors:  Luca Incrocci; Ruud C Wortel; Wendimagegn Ghidey Alemayehu; Shafak Aluwini; Erik Schimmel; Stijn Krol; Peter-Paul van der Toorn; Hanja de Jager; Wilma Heemsbergen; Ben Heijmen; Floris Pos
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

Review 8.  Current role of image-guided robotic radiosurgery (Cyberknife(®) ) for prostate cancer treatment.

Authors:  Thomas Seisen; Sarah J Drouin; Véronique Phé; Jérome Parra; Pierre Mozer; Marc-Olivier Bitker; Olivier Cussenot; Morgan Rouprêt
Journal:  BJU Int       Date:  2013-01-31       Impact factor: 5.588

9.  Image-guided radiotherapy for prostate cancer with cone beam CT: dosimetric effects of imaging frequency and PTV margin.

Authors:  Hemal Ariyaratne; Hayley Chesham; John Pettingell; Roberto Alonzi
Journal:  Radiother Oncol       Date:  2016-08-28       Impact factor: 6.280

10.  Determining intrafractional prostate motion using four dimensional ultrasound system.

Authors:  Mariwan Baker; Claus F Behrens
Journal:  BMC Cancer       Date:  2016-07-15       Impact factor: 4.430

View more
  2 in total

1.  SBRT for Localized Prostate Cancer: CyberKnife vs. VMAT-FFF, a Dosimetric Study.

Authors:  Marcello Serra; Fortuna De Martino; Federica Savino; Valentina D'Alesio; Cecilia Arrichiello; Maria Quarto; Filomena Loffredo; Rossella Di Franco; Valentina Borzillo; Matteo Muto; Gianluca Ametrano; Paolo Muto
Journal:  Life (Basel)       Date:  2022-05-10

2.  Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience.

Authors:  Helena Isabel Garcia Schüler; Matea Pavic; Michael Mayinger; Nienke Weitkamp; Madalyne Chamberlain; Cäcilia Reiner; Claudia Linsenmeier; Panagiotis Balermpas; Jerome Krayenbühl; Matthias Guckenberger; Michael Baumgartl; Lotte Wilke; Stephanie Tanadini-Lang; Nicolaus Andratschke
Journal:  Radiat Oncol       Date:  2021-11-14       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.